Foundation News

Check here for announcements, news, and information from Banner Health Foundation.

Banner Children’s teen patients make memories at “Prom by the Pool” thanks to Dunkin’ Joy in Childhood Foundation

08/02/2021

Prom has represented a cornerstone of American teenage life each spring, but every year, patients battling illness may have to miss this celebration. Earlier this summer, the Banner Health Foundation teamed up with the Dunkin’ Joy in Childhood Foundation to host a special “Prom by the Pool” event for teen patients to make memories to last a lifetime.

Banner Olive Branch Senior Center pivots quickly to feed low-income seniors during pandemic

07/01/2021

Recognizing the dire need for seniors in our community to be fed and cared for, the Nina Mason Pulliam Charitable Trust recently granted Banner Olive Branch Senior Center $100,000 to support this increased demand for services.

Hearts and minds intersect in new hope-filled home

07/01/2021

Adding heart transplantation to its full suite of services for patients with heart failure, Banner – University Medical Center Phoenix is now home to the only fully comprehensive heart failure treatment center in Arizona, providing state-of-the-art care—from prevention to transplant.

Partners in Wellness featuring Gopuff

06/23/2021

Banner Health Foundation and Banner Alzheimer's Foundation gratefully acknowledge new gifts of $10,000 or more from corporations, foundations, and local community groups that have invested in our organization in the past year through the Partners in Wellness program.

FDA Approves First Alzheimer’s Drug in 18 Years

06/11/2021

Earlier this week, the Food and Drug Administration announced a landmark approval of Biogen's aducanumab, the first new drug to slow Alzheimer’s disease in nearly two decades and the first drug attacking the underlying pathobiology.

The Banner Alzheimer’s Institute was a primary site involved in one of the pivotal phase 3 studies of aducanamab, with Drs. Eric Reiman, Pierre N. Tariot and Alireza Atri all serving in a variety of consulting, advocacy, and independent safety board review roles. They believe that the approved drug—and the completion of the other anti-amyloid drug trials in the next few years--will have a major impact on the field.